1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181114, NCT00428220
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA046, NCT00844649
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: H-22706, NCT00390182
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2005-0445, NCT00492817
|
|
6.
|
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: ID02-446, NCT00508443
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMDNJ-0120070076, 0120070076, NCT00553683
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: PANC0003, 95935, e1454, NCT00547144
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2006.018, IRB #HUM3315, NCT00593866
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2007-0248, NCT00634751
|
|
11.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TH-CR-402, NCT00743379
|
|
12.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 120
Sponsor: Other
Protocol IDs: 2007-0910, NCT00769483
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070411, NCT00819169
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2008-0780, NCT00831493
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12096, I2I-MC-JMMC, NCT00839332
|
|
16.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015580, NCT00841191
|
|
17.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ITL-002-CRYO, NCT00861107
|
|
18.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-114, NCT00948688
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A6-2208, NCT00959946
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RPCI I 150109, NCT00981162
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UTHSC-MS-02117, NCT00082862
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ID03-0009, 1R21CA104337, NCT00094445
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 5324, CINJ# 070501, NCT00161213
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCSF-06456, UCSF-H12191-29556-01, NCT00429858
|
